From June 23rd to 25th, the 17th Annual Meeting of the New Champions, also known as the 2026 Dalian Summer Davos, was held in Dalian. So Young founder, chairman, and CEO Jin Xing was invited to attend the forum and participate in discussions among business representatives.
Jin Xing stated that SoYoung is building the world's largest real-world database for non-invasive medical aesthetics and intelligent diagnostic infrastructure. China possesses a massive market, a comprehensive industrial system, and a wealth of real-world application scenarios, which provide unique advantages for the transition of artificial intelligence from technological breakthroughs to industrial implementation. For the medical aesthetics industry, the value of AI should not be limited to content generation and human-computer interaction. More importantly, it should enter the treatment room. Under the premise of ensuring medical safety, user privacy, and data compliance, AI can help doctors improve efficiency, assist institutions in maintaining quality, and enable high-quality medical services to benefit more consumers.
"The medical aesthetics industry has unique challenges: it is highly medical in nature with an extremely low tolerance for error. We absolutely cannot use consumers for experimentation or take medical risks," Jin Xing said. "The true indicator of AI's entry into the medical aesthetics industry is not how many questions a model can answer, but whether it can make each diagnosis and treatment safer, more transparent, and more precise."
During the forum, SoYoung disclosed its next-stage AI strategy for the first time. According to the plan, SoYoung will first promote the structured governance of multimodal information, including consultation dialogues, pre- and post-treatment images, doctor's treatment records, product and device parameters, treatment processes, and post-operative follow-ups. Based on user authorization, personal privacy protection, and data security, data from different stages will be interconnected, verifiable, and traceable.
At the application level, SoYoung will explore the use of vertical industry AI and agent technology to assist doctors in completing medical record documentation, pre-consultation information organization, risk alerts, treatment quality control, and post-operative follow-ups. This aims to reduce the time doctors spend on repetitive tasks, allowing them to focus more energy on medical judgment and patient communication.
Jin Xing stated, "Currently, we possess the world's largest database of real-world medical aesthetics scenarios, which is continuously used for training our self-developed medical aesthetics large models. We have already launched AI tools deployed on our branded app and customer communities, working in tandem with human customer service. Initially, they could only answer basic inquiries about procedures and products. Now, they can independently handle appointments, appointment changes, and reminders for promotional coupons."
Simultaneously, SoYoung will gradually explore the digital collection and analysis of doctors' operational processes. This involves linking a doctor's operational procedures, device parameters, and treatment plans with subsequent outcomes. This allows the professional experience of skilled doctors to be recorded, reviewed, and used for training, providing a data foundation for improving the overall medical quality of the industry.
"AI development is divided into two phases," Jin Xing explained. "The first half is data infrastructure, where we transform all offline clinics into smart clinics to complete full-scenario data collection. The second half is the large-scale commercial application of AI. It is expected that from the second half of this year to next year, AI tools will be widely adopted across all clinics. In the future, SoYoung will integrate its full suite of self-developed aesthetic models and standardized diagnosis and treatment systems with AI, aiming for AI's diagnostic capabilities to reach 80% of the level of senior consultants and doctors."
Jin Xing added, "In the past, downstream institutions primarily played the roles of product sales and medical service delivery. In the future, a scaled medical service network can also become a crucial infrastructure for industrial innovation. It can transmit real consumer demand, doctor experience, and treatment outcomes to the R&D end, making technological innovation closer to clinical practice and closer to consumers."
Comments